Actos (Pioglitazone)

The attorneys at Hollis Wright are currently investigating claims of involving the use of the Type 2 diabetic drug, Actos. Recent FDA warnings have indicated that using drugs containing pioglitazone for more than one year has been shown to increase the risk of bladder cancer. Drugs containing pioglitazone include Actos, Actoplus Met, Actoplus Met XR, and Duetact. If a loved one has taken any of these drugs containing pioglitazone and has been diagnosed with bladder cancer, please contact the attorneys at our firm today.

ActosIn September 2010, the FDA announced that the potential Actos bladder cancer risk was being evaluated. According to five-year data from the study, patients taking Actos for 12 months or longer had a 40% increased risk of developing bladder cancer. The risk increased with both dose size and duration of treatment.

In May 2011, a new study was published that provided further evidence that suggests Actos side effects may increase the risk of bladder cancer. FDA researchers have found that about one-fifth of all adverse event reports involving bladder cancer among diabetes drug users involved Actos.

Drug regulators in France and Germany have decided to suspend sales of the drug, essentially issuing an Actos recall, in June 2011, after a review of public insurance data revealed an increased occurrence of bladder cancer.

On June 16, 2011, the FDA announced that new warnings about the risk of bladder cancer from Actos will be added to the August 2011 medication label in the warnings and precautions section. Similar warnings will also be added to other medications that contain pioglitazone, the active ingredient in Actos, including Actoplus Met, ActoplusMet XR and Duetact.

The new warning issued August 4, 2011 states: The U.S. Food and Drug Administration (FDA) is informing the public that the Agency has approved updated drug labels for the pioglitazone-containing medicines to include safety information that the use of pioglitazone for more than one year may be associated with an increased risk of bladder cancer. FDA previously communicated these labeling changes to the public on June 15, 2011 (Drug Safety Communication)2.

More than 2.3 million prescriptions for the drug were issued in the United States in 2010. Actos has become one of the top selling drugs in the U.S. Furthermore, Actos has become the number one diabetic medication since Avandia's availability has become restricted. Actos sales totaled more than $4.3 billion last year.

All of the suits will contain allegations that the manufacturer failed to adequately research the side effects of Actos and failed to warn doctors and patients that pioglitazone-based drugs increase the risk of bladder cancer.

Client Reviews
"I, along with dad and family, want to thank your law firm for all that you did for us in representing my dad in his case. We were very satisfied with the settlement and the overall efforts by your firm. We also think that you and your staff made the process seem calm and smooth, yet professional. We could not have asked for a better attorney -- we would recommend you and your firm to anyone needing your expertise. Thanks so much for everything!!!" D. Hayes and C. Griffin, Clay County, AL
"Mr. Clay, I want to express my gratitude to you for agreeing to take my case. I know that I contacted your law firm with a fast approaching statute of limitations and some really significant challenges in proving my case. Thanks for the time, work, research and energy that you put into my case and for helping achieve a successful outcome. Peace and blessings to you and your family." V. Daniel, Philadelphia, PA
"The team at Hollis Wright were there for my husband when no one else would take his case. Not only did he work hard and recover money that we were owed. Without the help of Hollis Wright, we couldn't have afforded the care my husband needed and I would have lost him much sooner. We'll always consider you a part of the family." Donna B. Jemison, AL